BCRX – biocryst pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
BioCryst to Report Fourth Quarter 2025 Financial Results on February 26
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target lowered by analysts at Royal Bank Of Canada from $14.00 to $13.00. They now have an "outperform" rating on the stock.
Assessing BioCryst Pharmaceuticals (BCRX) Valuation After Recent Share Price Pressure And Rare Disease Pipeline Focus [Yahoo! Finance]
BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema 
Form 4 BIOCRYST PHARMACEUTICALS For: Jan 23 Filed by: Milne Jill C.
Form 3 BIOCRYST PHARMACEUTICALS For: Jan 23 Filed by: Milne Jill C.
Form 8-K/A BIOCRYST PHARMACEUTICALS For: Oct 14
Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 23
Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 12
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.